Wake Forest Clinical and Translational Science Award
维克森林临床和转化科学奖
基本信息
- 批准号:10667486
- 负责人:
- 金额:$ 392.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-13 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Academic supportAcademyAccelerationAchievementAddressAppalachian RegionAreaBiological ModelsCaringClinicalClinical ResearchClinical SciencesClinical TrialsClinical and Translational Science AwardsCollaborationsCommunitiesCommunity PhysicianContractsDataE-learningEducationEnvironmentEquityFosteringFundingGoalsHealthHealth systemHealthcareHealthcare SystemsIncentivesInformaticsInstitutional Review BoardsIntegrated Health Care SystemsInterdisciplinary StudyInvestmentsKnowledgeLaboratoriesLeadershipLearningLinkLongevityMentorsMethodsMissionModelingMulticenter TrialsNorth CarolinaParticipantPopulationPositioning AttributeProcessProgram DevelopmentReproducibilityResearchResearch InfrastructureResearch PersonnelResearch SupportResourcesRoleSafetyScholars ProgramScholarshipScienceScientific Advances and AccomplishmentsScientistSpecial PopulationSpeedStructureSystemTNFSF15 geneTestingTextilesTrainingTraining ProgramsTranslational ResearchTranslationsVisionWorkforce Developmentbiomedical informaticscatalystcommunity engagementdata sharingdesignearly-career facultyeducation researcheducation resourcesempowermentexperienceforestimplementation scienceimprovedinformatics infrastructureinnovationmembernext generationnonhuman primatepopulation healthpre-clinicalprecision medicineprogramsskillssuccesstooltranslational pipelinetranslational progressworkforce needs
项目摘要
Contact PD/PI: MCCLAIN, DONALD A.
Summary: Overall
When the Wake Forest (WF) Clinical and Translational Science Institute (CTSI) joined the CTSA consortium in
August 2015, our goal was to use our resources to catalyze WF’s transformation into an exemplary Learning
Health System in which “science, informatics, incentives, and culture are aligned for continuous improvement
and innovation, with best practices seamlessly embedded in the delivery process and new knowledge captured
as an integral by-product of the delivery experience.” We seek to extend this framework by integrating traditional
academic goals of T0 – T4 discovery, translation, and scholarship to form a new vision—the Academic Learning
Health System (aLHS). In our initial 3 years of funding, we have progressed towards our goal, establishing an
integrated research governance model, with the CTSI at its core, to realize efficiencies and address roadblocks
that hamper translational progress. We established Translational Catalysts to link the academic and clinical
enterprises and designed training programs to develop the skills our workforce needs to make the aLHS a reality.
We developed foundational informatics infrastructures essential to learning and growing, engaged communities
and stakeholders to integrate diverse perspectives into the fabric of our aLHS, and created a milieu for nurturing
innovative translational methods. We became a valued member of the CTSA national network, actively
collaborating with 20 CTSA hubs, and shared our world-class nonhuman primate models with the consortium.
With these successes, we turn to the next 5 years with strong assets in leadership, structure, scholarship, and
culture that uniquely position us to realize the aLHS ideal. We will fully integrate our new Translational Catalysts
– biomedical informatics, implementation science, precision medicine, healthcare innovation, and clinical trials –
and use them, along with incentives for academic engagement, to mobilize our growing clinical network. We will
develop, implement, and broadly disseminate improved methods and processes that will increase the efficiency,
safety, and reproducibility of preclinical and clinical science. We will partner with our community to integrate
special populations, and support health research across the lifespan. We will train our workforce for new roles,
especially in team environments, with new training programs (e.g., TL1 aLHS Scholars Program, the Learning
TREE online educational platform for individualized learning, Research-in-Action) and broaden our highly
successful KL2 training for early-career faculty. We will serve as a hub for biomedical informatics, accelerating
progress by enhancing existing resources, promoting collaboration and data sharing, and building new capacity.
We will remain committed to inclusiveness, mutual respect, and multiple perspectives to act as a catalyst for
change and healthy equity. We will further extend the reach of the aLHS into the communities served by our
expanding health system and will broaden our collaborations with other CTSA hubs to share best practices and
export the aLHS model – all guided by our ultimate goal of improving the health of our region and nation.
Page 243
Project Summary/Abstract
Contact PD/PI: MCCLAIN, DONALD A.
Narrative: Overall
The Wake Forest Clinical and Translational Science Institute seeks to become the model of an integrated
Academic Learning Health System in which we develop, implement, offer tailored training tools, and broadly
disseminate improved methods and processes to increase the efficiency, safety, and reproducibility of preclinical
and clinical science. We will build on our achievements to fully integrate our new Translational Catalysts –
biomedical informatics, implementation science, precision medicine, healthcare innovation and clinical trials –
and use them to develop and test initiatives, deploying research findings across our growing clinical network.
We will remain committed to training the next generation of scientists and leaders and will partner with our
community and CTSA hubs to integrate special populations and support research across the lifespan to extend
the benefits of our progress to the widest possible audience.
Page 244
联系PD/PI:McClain,DonaldA。
摘要:总体
当Wake Forest(WF)临床和转化科学研究所(CTSI)加入CTSA财团时
2015年8月,我们的目标是利用我们的资源将WF的转变催化为典范学习
卫生系统“科学,信息,激励措施和文化都保持一致,以持续改进
和创新,最佳实践无缝地嵌入到交付过程中,并捕获了新知识
作为交付体验不可或缺的副产品。“我们试图通过整合传统
T0 - T4发现,翻译和科学的学术目标是形成新愿景的学术学习
卫生系统(ALHS)。在我们最初的三年资金中,我们已经朝着我们的目标迈进了
综合研究治理模型与CTSI的核心,以实现效率并解决障碍
那个障碍转化的进步。我们建立了翻译催化剂,以将学术和临床联系起来
企业和设计培训计划以发展我们的劳动力所需的技能,以使ALH成为现实。
我们为学习和成长,参与社区所必需的基本信息基础设施开发了基础信息
利益相关者将潜水员的观点融入我们的ALH的结构,并创建了一个环境来培养
创新的翻译方法。我们成为CTSA国家网络的重要成员,积极地
与20个CTSA枢纽合作,并与财团分享了我们的世界一流的非人类私人模型。
有了这些成功,我们将在未来5年中拥有领导,结构,科学和
独特地定位我们实现ALHS理想的文化。我们将完全整合我们的新翻译催化剂
- 生物医学信息,实施科学,精密医学,医疗保健创新和临床试验 -
并使用它们,以及学术参与的激励措施,动员我们不断增长的临床网络。我们将
开发,实施和广泛传播改进的方法和过程,以提高效率,
临床前和临床科学的安全性和可重复性。我们将与社区合作以整合
特殊人群,并支持整个生命周期的健康研究。我们将培训员工新角色,
特别是在团队环境中,通过新的培训计划(例如TL1 ALHS学者计划,学习
树木在线教育平台,用于个性化学习,研究),并扩大了我们的高度
成功的KL2早期教师培训。我们将作为生物医学信息的枢纽,加速
通过增强现有资源,促进协作和数据共享以及建立新的能力来进行进展。
我们将继续致力于包容性,相互尊重和多种观点,以充当催化剂
改变和健康的公平。我们将进一步将ALH的覆盖范围扩展到我们的社区
扩大卫生系统,并将扩大我们与其他CTSA枢纽的合作,以分享最佳实践和
出口ALHS模型 - 所有人都以我们改善我们地区和国家健康的最终目标为指导。
第243页
项目摘要/摘要
联系PD/PI:McClain,DonaldA。
叙述:总体
Wake Forest临床和转化科学学院寻求成为综合的模型
我们开发,实施,提供量身定制的培训工具的学术学习卫生系统,并广泛
传播改进的方法和过程,以提高临床前的效率,安全性和可重复性
和临床科学。我们将基于我们的成就,以完全整合我们的新翻译催化剂 -
生物医学信息,实施科学,精密医学,医疗保健创新和临床试验 -
并使用它们来开发和测试计划,在不断增长的临床网络中部署研究结果。
我们将继续致力于培训下一代科学家和领导者,并将与我们的合作
社区和CTSA枢纽以整合特殊人群并支持整个生命周期的研究以延长
我们进步对最广泛的受众的好处。
第244页
项目成果
期刊论文数量(392)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systematic review of financial burden assessment in cancer: Evaluation of measures and utility among adolescents and young adults and caregivers.
- DOI:10.1002/cncr.33559
- 发表时间:2021-06-01
- 期刊:
- 影响因子:6.2
- 作者:Salsman JM;Danhauer SC;Moore JB;Ip EH;McLouth LE;Nightingale CL;Cheung CK;Bingen KM;Tucker-Seeley RD;Little-Greene D;Howard DS;Reeve BB
- 通讯作者:Reeve BB
Toward the Deimplementation of Computed Tomography Urogram for Patients With Low- to Intermediate-risk Microscopic Hematuria: A Mixed-method Study of Factors Influencing Continued Use.
- DOI:10.1097/upj.0000000000000429
- 发表时间:2023-09
- 期刊:
- 影响因子:0.8
- 作者:
- 通讯作者:
Exploiting maleimide-functionalized hyaluronan hydrogels to test cellular responses to physical and biochemical stimuli.
- DOI:10.1088/1748-605x/ac45eb
- 发表时间:2022-01-13
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Diet-Microbiota-Brain Axis in Alzheimer's Disease.
- DOI:10.1159/000515700
- 发表时间:2021
- 期刊:
- 影响因子:3.9
- 作者:Kincaid, Halle J.;Nagpal, Ravinder;Yadav, Hariom
- 通讯作者:Yadav, Hariom
Effect of Progression of Valvular Calcification on Left Ventricular Structure and Frequency of Incident Heart Failure (from the Multiethnic Study of Atherosclerosis).
- DOI:10.1016/j.amjcard.2020.08.017
- 发表时间:2020-11-01
- 期刊:
- 影响因子:0
- 作者:Fashanu OE;Upadhrasta S;Zhao D;Budoff MJ;Pandey A;Lima JAC;Michos ED
- 通讯作者:Michos ED
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jamy D Ard其他文献
Perspective: Impact of the National Academy of Sciences, Engineering, and Medicine Report on the Process for the 2020 Dietary Guidelines Advisory Committee
- DOI:
10.1093/advances/nmab023 - 发表时间:
2021-07-01 - 期刊:
- 影响因子:
- 作者:
Barbara O Schneeman;Jamy D Ard;Carol J Boushey;Regan L Bailey;Rachel Novotny;Linda G Snetselaar;Janet M de Jesus;Eve E Stoody - 通讯作者:
Eve E Stoody
Jamy D Ard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jamy D Ard', 18)}}的其他基金
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
使用双膦酸盐减轻减肥手术继发的骨质流失
- 批准号:
10440068 - 财政年份:2022
- 资助金额:
$ 392.8万 - 项目类别:
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
使用双膦酸盐减轻减肥手术继发的骨质流失
- 批准号:
10624846 - 财政年份:2022
- 资助金额:
$ 392.8万 - 项目类别:
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial
1/2,抗肥胖药物芬特明长期有效性临床协调中心:LEAP 试验
- 批准号:
10304557 - 财政年份:2021
- 资助金额:
$ 392.8万 - 项目类别:
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial
1/2,抗肥胖药物芬特明长期有效性临床协调中心:LEAP 试验
- 批准号:
10513404 - 财政年份:2021
- 资助金额:
$ 392.8万 - 项目类别:
Calorie Restriction & Body Composition, Function, & QoL in Older Adults
热量限制
- 批准号:
8122197 - 财政年份:2009
- 资助金额:
$ 392.8万 - 项目类别:
Calorie Restriction & Body Composition, Function, & QoL in Older Adults
热量限制
- 批准号:
8521036 - 财政年份:2009
- 资助金额:
$ 392.8万 - 项目类别:
Calorie Restriction & Changes in Body Composition, Disease, Function, & QoL in Ol
热量限制
- 批准号:
7741538 - 财政年份:2009
- 资助金额:
$ 392.8万 - 项目类别:
Calorie Restriction & Body Composition, Function, & QoL in Older Adults
热量限制
- 批准号:
8309182 - 财政年份:2009
- 资助金额:
$ 392.8万 - 项目类别:
Calorie Restriction & Changes in Body Composition, Disease, Function, & QoL in Ol
热量限制
- 批准号:
7940811 - 财政年份:2009
- 资助金额:
$ 392.8万 - 项目类别:
相似国自然基金
湖州师范学院理论物理强子共振态和核物理方向学术交流与平台建设
- 批准号:
- 批准年份:2021
- 资助金额:50 万元
- 项目类别:
“抗疫精神”对医护职业偏好、行为偏好的短期与长期影响:基于医务人员和医学院学生的研究
- 批准号:72173093
- 批准年份:2021
- 资助金额:48 万元
- 项目类别:面上项目
湖州师范学院理论物理奇特核结构与反应方向学术交流与平台建设
- 批准号:
- 批准年份:2020
- 资助金额:50 万元
- 项目类别:专项基金项目
数学院士专家大学中学系列科普活动
- 批准号:12026425
- 批准年份:2020
- 资助金额:20.0 万元
- 项目类别:数学天元基金项目
量子体系中的能量传输与能量转换学院
- 批准号:11981240427
- 批准年份:2019
- 资助金额:1.5 万元
- 项目类别:国际(地区)合作与交流项目
相似海外基金
Unified, Scalable, and Reproducible Neurostatistical Software
统一、可扩展且可重复的神经统计软件
- 批准号:
10725500 - 财政年份:2023
- 资助金额:
$ 392.8万 - 项目类别:
Development and Pilot Study of Primary Care Loneliness Interventions to Prevent Suicide
预防自杀的初级保健孤独干预措施的开发和试点研究
- 批准号:
10646959 - 财政年份:2023
- 资助金额:
$ 392.8万 - 项目类别:
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
- 批准号:
10763967 - 财政年份:2023
- 资助金额:
$ 392.8万 - 项目类别:
BiOengineering Research Education to AcceLerate Innovation in STEM
生物工程研究教育加速 STEM 创新
- 批准号:
10652133 - 财政年份:2023
- 资助金额:
$ 392.8万 - 项目类别:
Neurosurgeon Research Career Development Program (NRCDP)
神经外科医生研究职业发展计划 (NRCDP)
- 批准号:
10541698 - 财政年份:2023
- 资助金额:
$ 392.8万 - 项目类别: